Key statistics
On Thursday, ARS Pharmaceuticals Inc (SPRY:NMQ) closed at 14.86, -9.94% below its 52-week high of 16.50, set on Aug 20, 2024.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 14.50 |
---|---|
High | 15.10 |
Low | 14.12 |
Bid | 14.50 |
Offer | 15.15 |
Previous close | 14.05 |
Average volume | 1.09m |
---|---|
Shares outstanding | 96.94m |
Free float | 74.20m |
P/E (TTM) | -- |
Market cap | 1.36bn USD |
EPS (TTM) | -0.466 USD |
Data delayed at least 15 minutes, as of Sep 19 2024 21:00 BST.
More ▼
- ARS Pharmaceuticals to Participate in the 2024 Cantor Global Healthcare Conference
- ARS Pharmaceuticals Submits sNDA to FDA for neffy® 1 mg Dose for Pediatric Patients with Type I Allergic Reactions Who Weigh 15 to 30 kg (33-66 lbs.)
- ARS Pharmaceuticals Launches Pre-Ordering Services for neffy® to Help Patients Access the First and Only Needle-Free Treatment for Type I Allergic Reactions, Including Anaphylaxis
- EURneffy (adrenaline nasal spray) Approved in the EU as the First and Only Needle-Free Emergency Treatment of Allergic Reactions (anaphylaxis)
- ARS Pharmaceuticals Receives FDA Approval of neffy® (epinephrine nasal spray), the First and Only Needle-Free Treatment for Type I Allergic Reactions, Including Anaphylaxis
- ARS Pharmaceuticals to Participate in the 2024 Wedbush PacGrow Healthcare Conference
- ARS Pharmaceuticals Provides Business Highlights and Reports Second Quarter 2024 Financial Results
- ARS Pharmaceuticals Announces EURneffy (adrenaline nasal spray) Recommended for Approval by CHMP for Emergency Treatment of Allergic Reactions (anaphylaxis)
- ARS Pharmaceuticals Highlights neffy Regulatory Progress and Reports First Quarter 2024 Financial Results
- ARS Pharmaceuticals Submits Response for neffy® (epinephrine nasal spray) Marketing Authorization Application to EMA’s CHMP and Enters License Agreement with CSL Seqirus for Commercialization of neffy in Australia and New Zealand
More ▼